Effects of Cardiovascular Health Education Program on Community-dwelling Older Adults at Risk of ASCVD

Sponsor
The Hong Kong Polytechnic University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05031377
Collaborator
(none)
80
2
36

Study Details

Study Description

Brief Summary

Despite older adults being exposed to an increased risk of atherosclerotic cardiovascular disease (ASCVD), they are generally underrepresented in cardiovascular prevention programmes. The aim of this study is to assess the feasibility of implementing an integrated exercise and cardiovascular health education programme (HE programme) on older adults at risk of ASCVD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: HE programme
  • Behavioral: Usual care
N/A

Detailed Description

The study is a two-arm pilot randomized controlled trial. (1) The control group will receive a basic lifestyle modification talk and governmental education leaflets. (2) The experimental group will receive an integrated exercise and health education programme (HE programme) based on self-efficacy theory. Physical activity level, exercise self-efficacy and ASCVD risk profile including blood pressure, cardiac endurance, and anthropometric outcomes will be investigated via physiological assessments, medical history-taking or questionnaires at baseline, Week 6, and Week 12. Meanwhile, study feasibility will be primarily evaluated in terms of programme acceptability, intervention integrity, recruitment rate and retention rate throughout the process and at Week 12.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
The Effects of a Cardiovascular Health Education Program on Community-dwelling Older Adults at Risk of Atherosclerotic Cardiovascular Diseases: A Pilot Randomized Controlled Trial
Anticipated Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Arm: Integrated Intervention

Receive an integrated exercise and cardiovascular health education programme (HE programme)

Behavioral: HE programme
Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.

Sham Comparator: Control

Receive usual care

Behavioral: Usual care
Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.

Outcome Measures

Primary Outcome Measures

  1. Physical activity level (total score) [At baseline, at Week 6, and at Week 12]

    The physical activity level will be measured by the Chinese Version of Physical Activity Scale for the Elderly (PASE-C). The total score (from zero to 400 or above) is quantified based on frequency values and weights for these activities. The higher the score, the higher the level of physical activity.

  2. Physical activity level (classification of physical activity level) [At baseline, at Week 6, and at Week 12]

    The physical activity level will be measured by the Chinese version of International Physical Activity Questionnaire-short form (IPAQ-C-short form). Participants are classified into "inactive", "minimally active" or "health enhancing physical activity (HEPA) active" based on their physical activity levels.

Secondary Outcome Measures

  1. Exercise self-efficacy [At baseline, at Week 6, and at Week 12]

    Exercise self-efficacy will be measured via the Chinese version of Self-Efficacy for Exercise (SEE-C). The total score ranges from 0 to 90. The higher the score, the greater the exercise self-efficacy.

  2. ASCVD risk profiles (Blood pressure, weight, height, BMI & waist circumference, heart rate) [At baseline, at Week 6, and at Week 12]

    The ASCVD risk profiles will be assessed by physical evaluations carried out by blinded, trained outcome assessors.

  3. ASCVD risk profiles (2-minute walk test) [At screening stage, at Week 6, and at Week 12]

    2-minute walk test will be adopted to examine aerobic capacity and self-paced walking capacity by measuring the walking distance covered at two minutes. It will be assessed by blinded, trained outcome assessors.

  4. Acceptability of the program to participants [At Week 12]

    It will be measured by a self-developed questionnaire

  5. Acceptability of the program to outcome assessors [After the outcome assessors have finished their duties]

    It will be measured by a self-developed questionnaire completed by outcome assessors

  6. Acceptability of the program to lecture deliverers [After the lecture deliverers have finished their duties]

    It will be measured by a self-developed questionnaire completed by lecture deliverers

  7. Adverse events throughout the program [Throughout the study period]

    Unfavorable or unintended events regarding the programme reported by participants throughout the study period.

  8. Program safety evaluated by participants [At Week 12]

    It will be measured via a self-developed questionnaire completed by participants

  9. Eligibility rate [At baseline]

    The number of eligible potential participants divided by the number of screened people

  10. Recruitment rate [At baseline]

    The percentage of participants who consent to join the study and being recruited

  11. Retention rate [At baseline, at Week 6 and at Week 12]

    The percentage of participants remaining in the study

  12. Lecture attendance rate [Immediately after education session]

    The number of participants in the control group who attend the education talk divided by the number of participants who are randomized into the control group The number of participants in the experimental group who attend the education session divided by the number of participants who are randomized into the experimental group The number of participants in the two groups who attend the education session divided by the number of randomized participants

  13. Adherence to intervention [At Week 6 and at Week 12]

    The number of participants in the experimental group who practice the tailor-made exercise learned during the intervention divided by the number of participants in the experimental group Experimental group's frequency in performing tailor-made exercise related to the recommended exercise dosage

  14. Attendance rate to data collection [At baseline, at Week 6 and at Week 12]

    The number of participants in the control group who attend the data collection divided by the number of participants who are randomized into the control group The number of participants in the experimental group who attend the data collection divided by the number of participants who are randomized into the experimental group The number of participants who attend the data collection divided by the number of randomized participants

  15. Questionnaire completion rate [At baseline, at Week 6 and at Week 12]

    The number of participants who complete the questionnaire divided by the number of distributed questionnaires

  16. Missing data [At baseline, at Week 6 and at Week 12]

    The percentage of missing data

  17. Structured questionnaire [At baseline]

    The questionnaire will primarily include patient demographics, medical history, lifestyle patterns, medication use and physical fitness evaluation data, etc.

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Chinese adults ≧60 years old

  • Having at least one ASCVD risk factor

  • Pass the cardiovascular fitness evaluation

  • Able to write and read Chinese, and communicate in Cantonese;

  • Possess a mobile phone and able to make use of the phone in reading SMS

Exclusion Criteria:
  • Visually impaired, hearing impaired, or suffer from cognitive, psychiatric, or muscular disorder

  • Having a history of attending similar cardiovascular prevention program

  • Having a previous history of coronary heart disease or stroke

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • The Hong Kong Polytechnic University

Investigators

  • Study Director: Ka Yan Ho, PhD, The Hong Kong Polytechnic University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr Eva Ho, Assistant Professor, The Hong Kong Polytechnic University
ClinicalTrials.gov Identifier:
NCT05031377
Other Study ID Numbers:
  • ASCVD_OlderAudlts
First Posted:
Sep 1, 2021
Last Update Posted:
Sep 1, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr Eva Ho, Assistant Professor, The Hong Kong Polytechnic University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 1, 2021